46.48
price up icon5.21%   2.30
pre-market  Vorhandelsmarkt:  46.00   -0.48   -1.03%
loading
Schlusskurs vom Vortag:
$44.18
Offen:
$46.59
24-Stunden-Volumen:
414.25K
Relative Volume:
0.95
Marktkapitalisierung:
$2.24B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.59%
1M Leistung:
-3.45%
6M Leistung:
+209.04%
1J Leistung:
+292.57%
1-Tages-Spanne:
Value
$44.43
$46.65
1-Wochen-Bereich:
Value
$43.00
$47.27
52-Wochen-Spanne:
Value
$6.71
$49.25

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name
Firmenname
Maze Therapeutics Inc
Name
Telefon
(650) 850-5070
Name
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Name
Mitarbeiter
125
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
MAZE's Discussions on Twitter

Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MAZE
Maze Therapeutics Inc
46.48 2.13B 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.89 120.48B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
787.50 81.05B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
749.56 46.33B 4.16B 1.29B 734.26M 19.59
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.30 42.26B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.02 32.87B 5.36B 287.73M 924.18M 2.5229

Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-12-04 Eingeleitet Wells Fargo Overweight
2025-11-14 Eingeleitet Raymond James Outperform
2025-09-02 Eingeleitet BTIG Research Buy
2025-07-23 Eingeleitet H.C. Wainwright Buy
2025-07-08 Eingeleitet Wedbush Outperform

Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten

pulisher
06:50 AM

Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside - TipRanks

06:50 AM
pulisher
Mar 04, 2026

MAZE: Lead kidney and metabolic disease programs advance toward pivotal data with strong financial backing - TradingView

Mar 04, 2026
pulisher
Mar 04, 2026

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up Following Analyst Upgrade - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at Guggenheim - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE) Sees Significant Growth in Short Interest - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Aug Update: What analysts say about Maze Therapeutics Inc stockWeekly Profit Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn

Mar 03, 2026
pulisher
Mar 01, 2026

Pullback Watch: Is Iveda Solutions Inc a good ESG investmentMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Mar 01, 2026
pulisher
Feb 27, 2026

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Innovator with a 10.77% Potential Upside - DirectorsTalk Interviews

Feb 27, 2026
pulisher
Feb 25, 2026

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times

Feb 25, 2026
pulisher
Feb 25, 2026

Maze Therapeutics Inc CEO set for TD Cowen Health Care event - Traders Union

Feb 25, 2026
pulisher
Feb 24, 2026

MAZE Technical Analysis & ETF Price Forecast - Intellectia AI

Feb 24, 2026
pulisher
Feb 24, 2026

Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst - TipRanks

Feb 24, 2026
pulisher
Feb 20, 2026

Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech With A 9.78% Upside Potential - DirectorsTalk Interviews

Feb 20, 2026
pulisher
Feb 20, 2026

Is Maze Therapeutics Inc. forming bullish engulfing patterns2025 Year in Review & Stepwise Entry and Exit Trade Signals - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Latest MAZE ETF News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 20, 2026
pulisher
Feb 18, 2026

Zifo Partners With Maze Therapeutics on Managing Biobank Data - Contract Pharma

Feb 18, 2026
pulisher
Feb 18, 2026

Zifo and Maze Therapeutics Partner to Power Precision Medicine - The Malaysian Reserve

Feb 18, 2026
pulisher
Feb 18, 2026

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - AOL.com

Feb 18, 2026
pulisher
Feb 18, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Feb 18, 2026
pulisher
Feb 17, 2026

Earnings Recap: How liquid is Maze Therapeutics Inc stockQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn

Feb 17, 2026
pulisher
Feb 16, 2026

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - The Motley Fool

Feb 16, 2026
pulisher
Feb 15, 2026

Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened - MSN

Feb 15, 2026
pulisher
Feb 15, 2026

MAZE Should I Buy - Intellectia AI

Feb 15, 2026
pulisher
Feb 14, 2026

Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return - Yahoo Finance

Feb 14, 2026
pulisher
Feb 14, 2026

Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit - MarketBeat

Feb 14, 2026
pulisher
Feb 13, 2026

Frazier Life Sciences discloses Maze Therapeutics (MAZE) 9% ownership and warrants cap - Stock Titan

Feb 13, 2026
pulisher
Feb 13, 2026

Bull Bear: What analysts say about Maze Therapeutics Inc stockGlobal Markets & Weekly High Return Opportunities - baoquankhu1.vn

Feb 13, 2026
pulisher
Feb 09, 2026

Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Sahm

Feb 09, 2026
pulisher
Feb 08, 2026

IPO Launch: Is Maze Therapeutics Inc forming a bullish divergenceJuly 2025 WrapUp & Consistent Return Investment Signals - baoquankhu1.vn

Feb 08, 2026
pulisher
Feb 07, 2026

Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Feb 07, 2026
pulisher
Feb 06, 2026

Maze Therapeutics, Inc. (MAZE): Investor Outlook on Strong Buy Ratings and 12.50% Upside Potential - DirectorsTalk Interviews

Feb 06, 2026
pulisher
Feb 05, 2026

Maze Therapeutics Secures New $200 Million Loan Facility - The Globe and Mail

Feb 05, 2026
pulisher
Feb 04, 2026

Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat

Feb 04, 2026
pulisher
Feb 04, 2026

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 15,000 Shares of Stock - MarketBeat

Feb 04, 2026
pulisher
Feb 04, 2026

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail

Feb 04, 2026
pulisher
Feb 04, 2026

Maze Therapeutics Signs Loan and Security Agreement With Hercules Capital - TradingView

Feb 04, 2026
pulisher
Feb 04, 2026

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times

Feb 04, 2026
pulisher
Feb 03, 2026

Maze Therapeutics stock hits all-time high at 47.47 USD By Investing.com - Investing.com Nigeria

Feb 03, 2026
pulisher
Feb 03, 2026

Maze Therapeutics stock hits all-time high at 47.47 USD - Investing.com

Feb 03, 2026
pulisher
Feb 03, 2026

Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat

Feb 03, 2026
pulisher
Feb 03, 2026

Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock - Defense World

Feb 03, 2026
pulisher
Feb 02, 2026

Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock - AOL.com

Feb 02, 2026
pulisher
Feb 02, 2026

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock - MarketBeat

Feb 02, 2026
pulisher
Feb 01, 2026

Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat

Feb 01, 2026
pulisher
Jan 30, 2026

Maze Therapeutics, Inc. (MAZE): Investor Outlook And 9.88% Potential Upside - DirectorsTalk Interviews

Jan 30, 2026
pulisher
Jan 28, 2026

Washington University Takes Position in Maze Therapeutics, Inc. $MAZE - MarketBeat

Jan 28, 2026
pulisher
Jan 28, 2026

Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright - Investing.com Canada

Jan 28, 2026
pulisher
Jan 28, 2026

Equities Analysts Set Expectations for MAZE FY2030 Earnings - MarketBeat

Jan 28, 2026
pulisher
Jan 26, 2026

Maze Therapeutics Rings the Closing Bell - Nasdaq

Jan 26, 2026
pulisher
Jan 26, 2026

Maze Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Jan 26, 2026
pulisher
Jan 25, 2026

Maze Therapeutics (NASDAQ:MAZE) Raised to "Hold" at Wall Street Zen - MarketBeat

Jan 25, 2026

Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)

Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$47.43
price down icon 0.11%
$29.52
price up icon 6.00%
$57.80
price up icon 15.99%
$103.80
price up icon 3.02%
$149.88
price up icon 1.96%
biotechnology ONC
$299.02
price up icon 0.67%
Kapitalisierung:     |  Volumen (24h):